Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Adc Therapeutics Sa
(NY:
ADCT
)
2.900
+0.030 (+1.05%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Adc Therapeutics Sa
< Previous
1
2
3
4
Next >
ADCT Stock Earnings: ADC Therapeutics Beats EPS, Misses Revenue for Q2 2024
August 06, 2024
ADCT stock results show that ADC Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
Via
InvestorPlace
7 Growth Stocks to Buy for Under $5 for Massive Gains
July 11, 2024
Although growth stocks under $5 are inherently risky and unpredictable, their very nature also facilitates robust upside potential.
Via
InvestorPlace
Intapp, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session
July 08, 2024
Via
Benzinga
Stocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a Budget
June 13, 2024
Since wealth without health is utterly meaningless, investors may have some confidence with these biotech stocks to buy.
Via
InvestorPlace
ADCT Stock Earnings: ADC Therapeutics Beats EPS, Misses Revenue for Q1 2024
May 06, 2024
ADCT stock results show that ADC Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
A Preview Of ADC Therapeutics's Earnings
March 12, 2024
Via
Benzinga
ADC Therapeutics - Time For A Turn-Around?
February 27, 2024
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates for patients suffering from hematological malignancies and solid tumors.
Via
Talk Markets
Analyst Expectations for ADC Therapeutics's Future
November 20, 2023
Via
Benzinga
The Latest Analyst Ratings for ADC Therapeutics
September 12, 2023
Via
Benzinga
BioNTech Reports Downbeat Earnings, Joins Medical Properties Trust And Other Big Stocks Moving Lower In Monday's Pre-Market Session
May 06, 2024
Via
Benzinga
Medifast Reports Mixed Results, Joins Coursera, Chegg And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
April 30, 2024
Via
Benzinga
Dollar Tree Reports Weak Earnings, Joins Tesla, Arcos Dorados And Other Big Stocks Moving Lower On Wednesday
March 13, 2024
U.S. stocks were mixed, with the Dow Jones index surging more than 100 points on Wednesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Alaska Air To Rally Around 36%? Here Are 10 Top Analyst Forecasts For Tuesday
February 20, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
A Preview Of ADC Therapeutics's Earnings
August 07, 2023
Via
Benzinga
4 Analysts Have This to Say About ADC Therapeutics
July 25, 2023
Via
Benzinga
Earnings Scheduled For March 13, 2024
March 13, 2024
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million.
Via
Benzinga
The 3 Biotech Stocks That Could Make Your February Unforgettable
February 15, 2024
After a blistering hot year of biotech M&A, we’ll see more of the same in 2024. That could be great news for these hot biotech stocks.
Via
InvestorPlace
The 3 Most Undervalued Biotech Stocks to Buy in February 2024
February 08, 2024
With patience, some of the most undervalued biotech stocks can create massive wealth, such as these three to consider.
Via
InvestorPlace
Why BEST Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
November 06, 2023
Gainers Carbon Revolution Public Limited (NASDAQ: CREV) shares surged 358% to $134.37 in pre-market trading after gaining 100% on Friday. The company’s stock began trading on Friday following merger...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2023
August 10, 2023
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
July 25, 2023
On Tuesday, 56 companies set new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
July 21, 2023
On Friday, 54 companies hit new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
July 24, 2023
On Monday morning, 70 companies achieved new lows for the year.
Via
Benzinga
ADC Therapeutics Pulls Plug On Mid-Stage Zynlonta Study In Untreated Lymphoma Patients After Patient Deaths
July 21, 2023
ADC Therapeutics SA (NASDAQ: ADCT) announced that it plans to discontinue the Phase 2 LOTIS-9 trial evaluating Zynlonta (loncastuximab tesirine-lpyl) and rituximab in unfit or frail patients with...
Via
Benzinga
Dow Rises More Than 200 Points; Adial Pharmaceuticals Shares Spike Higher
July 11, 2023
U.S. stocks traded higher toward the end of trading, with the Dow Jones surging more than 200 points on Tuesday. The Dow traded up 0.73% to 34,193.60 while the NASDAQ rose 0.25% to 13,720.16. The S&P...
Via
Benzinga
Why Siyata Mobile Shares Are Trading Lower By 21%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
July 11, 2023
Gainers CytoMed Therapeutics Limited (NASDAQ: GDTC) shares climbed 129.5% to $8.01 after gaining 9% on Monday.
Via
Benzinga
Crude Oil Rises 2%; ADC Therapeutics Shares Plummet
July 11, 2023
U.S. stocks traded higher midway through trading, with the Dow Jones surging over 100 points on Tuesday. The Dow traded up 0.41% to 34,082.47 while the NASDAQ rose 0.29% to 13,725.52. The S&P 500, also...
Via
Benzinga
Dow Jumps Over 100 Points; US Small Business Optimism Index Tops Estimates
July 11, 2023
U.S. stocks traded higher this morning, with the Dow Jones gaining over 100 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.40% to 34,080.13 while the NASDAQ rose 0.23% to...
Via
Benzinga
ADC Therapeutics Stock Is Plunging Today - What's Going On?
July 11, 2023
ADC Therapeutics SA (NASDAQ: ADCT) has voluntarily paused enrollment of new patients in the Phase 2 LOTIS-9 trial evaluating Zynlonta (loncastuximab tesirine-lpyl) and rituximab (Lonca-R) in unfit or...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 24, 2023
April 24, 2023
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.